Docetaxel in combination with either cisplatin or gemcitabine in unresectable non-small cell lung carcinoma: a randomized phase II study by the Japan Lung Cancer Cooperative Clinical Study Group (Q80100776)

From Wikidata

Jump to navigation Jump to search

scientific article published on 01 June 2006

Language	Label	Description	Also known as
English	Docetaxel in combination with either cisplatin or gemcitabine in unresectable non-small cell lung carcinoma: a randomized phase II study by the Japan Lung Cancer Cooperative Clinical Study Group	scientific article published on 01 June 2006

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409898%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Docetaxel in combination with either cisplatin or gemcitabine in unresectable non-small cell lung carcinoma: a randomized phase II study by the Japan Lung Cancer Cooperative Clinical Study Group (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409898%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Nobuyuki Katakami

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409898%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Yuichi Takiguchi

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409898%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Kozo Yoshimori

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409898%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Hiroshi Isobe

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409898%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Akihiro Bessho

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409898%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Akinobu Yoshimura

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409898%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Hisanobu Niitani

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409898%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

publication date

1 June 2006

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409898%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Journal of Thoracic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409898%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409898%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409898%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

447-453

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409898%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931610-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931610-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931610-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG)

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931610-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931610-5

7 January 2021

based on heuristic

inferred from DOI database lookup

First-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: A multicenter phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931610-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicenter phase II trial of docetaxel and carboplatin in patients with stage IIIB and IV non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931610-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931610-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931610-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931610-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931610-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931610-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931610-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II trial of gemcitabine and docetaxel in patients with chemotherapy-naive, advanced nonsmall cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931610-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel and Gemcitabine administered on days 1 and 8 for metastatic non-small cell lung carcinoma (NSCLC): a phase II multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931610-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931610-5

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931610-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931610-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931610-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin.

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931610-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination chemotherapy without cisplatin in the treatment of advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931610-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination of chemotherapy without platinum compounds in the treatment of advanced non-small cell lung cancer: a systematic review of phase III trials

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931610-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931610-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931610-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase I/II study comparing regimen schedules of gemcitabine and docetaxel in Japanese patients with stage IIIB/IV non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931610-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of a fixed dose-rate infusion of gemcitabine associated with docetaxel in advanced non-small-cell lung carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931610-5

7 January 2021

based on heuristic

inferred from DOI database lookup

First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931610-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931610-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931610-5

7 January 2021

based on heuristic

inferred from DOI database lookup

High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2931610-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1556-0864(15)31610-5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409898%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409898%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q80100776&oldid=1812242664"